Please login to the form below

Not currently logged in
Email:
Password:

Asceneuron appoints chief medical officer

Novartis’ Michael Ryan joins the neurodegenerative diseases specialist

Asceneuron Michael RyanLausanne, Switzerland-based Asceneuron has appointed Michael Ryan as its new chief medical officer.

Ryan brings over 15 years of central nervous system clinical research experience to the role, and takes on responsibility for Asceneuron's pipeline of innovative small molecules and progressing tau modifiers through its clinic.

He joins the neurodegenerative diseases specialist from Novartis, where he had served as vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.

Prior to this, Ryan was senior director of global research and development at Pfizer, before becoming its senior director of vaccine clinical research and leading the firm's immunotherapy programme in Alzheimer's disease.

He has also held senior clinical positions at MSD Research Laboratories and Wyeth Research in the US.

Dirk Beher, chief executive officer of Asceneuron, said: “We are delighted to welcome Michael to the Asceneuron team.

“His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for the treatment of a number of orphan CNS disorders.

“We look forward to working with Michael in addressing this high unmet medical need and developing our pipeline to bring our innovative small-molecule therapeutics to patients.”

19th December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics